Trends and projection of incidence, mortality, and disability-adjusted life years of HIV in the Middle East and North Africa (1990-2030).


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 08 2023
Historique:
received: 08 01 2023
accepted: 16 08 2023
medline: 28 8 2023
pubmed: 25 8 2023
entrez: 24 8 2023
Statut: epublish

Résumé

Evidence shows a growing trend of the HIV epidemic in the Middle East and North Africa (MENA). We aimed to project the incidence, mortality, and disability-adjusted life years (DALY) in the region from 1990 to 2019 and assess its trend by 2025, and 2030. We extracted the HIV incidence, mortality, and DALY data from the Global Burden of Disease (GBD) and UNAIDS databases. The joinpoint regression model was used to examine changes in HIV trends. The trend changes were estimated by average annual percent change (AAPC). In most countries, an increasing trend was observed in HIV incidence, mortality, and DALY. Specifically, the highest growth in the annual incidence rate was related to Egypt (AAPC = 14.4, GBD) and Iran (AAPC = 9.6, UNAIDS). Notably, Qatar (AAPC = - 5.6, GBD), Bahrain (AAPC = - 3.3, GBD), and Somalia (AAPC = - 4.2, UNAIDS) demonstrated a significant reduction in incidence. Regarding mortality rates, Djibouti (AAPC = 24.2, GBD) and Iran (AAPC = 16.2, UNAIDS) exhibited a significant increasing pattern. Furthermore, the estimated increase in incidence by 2030 was most marked in Djibouti (985%) and Iran (174%). Iran (422%) and Egypt (339%) showed a prominent rise in mortality rates. GBD data showed 16 countries had an increasing pattern in DALY in both genders. According to age and period effects, there was a significant upward trend in incidence, mortality rates, and DALY. Findings highlighted the urgent need for improved prevention and treatment services, including expanding access to HIV testing, promoting safe practices, increasing antiretroviral therapy coverage, and supporting targeted interventions for high-risk populations.

Identifiants

pubmed: 37620356
doi: 10.1038/s41598-023-40743-z
pii: 10.1038/s41598-023-40743-z
pmc: PMC10449905
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13859

Informations de copyright

© 2023. Springer Nature Limited.

Références

Int J STD AIDS. 2021 Mar;32(3):257-265
pubmed: 33525959
BMC Public Health. 2022 Sep 8;22(1):1705
pubmed: 36076214
Ann Med Surg (Lond). 2022 May 20;78:103842
pubmed: 35734645
Lancet HIV. 2022 Jul;9(7):e496-e505
pubmed: 35777411
Cancer. 2012 Feb 15;118(4):1091-9
pubmed: 22228565
Trop Med Infect Dis. 2021 Sep 24;6(4):
pubmed: 34698297
Med J Islam Repub Iran. 2021 Dec 1;35:159
pubmed: 35341084
Lancet HIV. 2022 Jul;9(7):e454-e455
pubmed: 35777405
Lancet. 2010 Jul 24;376(9737):268-84
pubmed: 20650523
Int J Health Policy Manag. 2016 Aug 23;6(2):65-69
pubmed: 28812781
J Int AIDS Soc. 2018 Mar;21(3):e25102
pubmed: 29577623
Sex Transm Infect. 2013 Nov;89 Suppl 3:iii10
pubmed: 23748677
Cien Saude Colet. 2021 Jan;26(1):297-307
pubmed: 33533851
Lancet HIV. 2019 Dec;6(12):e809-e811
pubmed: 31439533
AIDS. 2010 Jul;24 Suppl 2:S25-32
pubmed: 20610945
Cancer. 2012 Feb 15;118(4):1100-9
pubmed: 22228583
Lancet HIV. 2020 May;7(5):e311-e313
pubmed: 31928930
Int J Infect Dis. 2016 Mar;44:66-73
pubmed: 26948920
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Feb 28;43(2):210-215
pubmed: 29559608
Int J Drug Policy. 2016 May;31:168-71
pubmed: 27140430
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
AIDS. 2021 Mar 15;35(4):529-542
pubmed: 33252485
Glob Health Action. 2019;12(1):1662685
pubmed: 31510887
Sex Transm Infect. 2012 Dec;88 Suppl 2:i11-6
pubmed: 23172341

Auteurs

Zahra Khorrami (Z)

Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard St., Pasdaran Ave., Tehran, Iran.

Mohammadreza Balooch Hasankhani (M)

Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.

Mehrdad Khezri (M)

Department of Epidemiology, New York University School of Global Public Health, New York, NY, United States.
HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.

Ali Jafari-Khounigh (A)

Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Yones Jahani (Y)

Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.

Hamid Sharifi (H)

HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. hsharifi@kmu.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH